FairJourney Biologics
Marc van Dijk currently serves as the Chief Scientific Officer for Discovery and Engineering at FairJourney Biologics since December 2024. Prior to this role, Marc held the position of Chief Scientific Officer at MiNK Therapeutics from March 2022 to December 2024, overseeing research teams in Cambridge, UK, and Lexington, MA. Marc's extensive career includes significant roles at Agenus as Chief Technology Officer and Executive Director of Platform Technology, leading platform technology initiatives at AgenTus Therapeutics, and contributions as Vice President of Antibody Technology at Genmab. Academic credentials include a Postdoctoral degree in Molecular Biology from UC San Diego and a Ph.D. in Molecular Biology from Utrecht University.
This person is not in any teams
This person is not in any offices
FairJourney Biologics
FairJourney Biologics is a privately established company with an outstanding track record of biotech and biopharmaceutical partners (Merus, argenX, BMS, Bayer, among others), offering a range of assets and services on antibody discovery, engineering, production, characterization up to cell line development stages. Our naïve and immune libraries from humans, rodents and llama, together with our know-how and internal technological development allow us to contribute to the pipeline of our partners on complex targets, leading to 14 known antibodies in the clinic. More recently, FairJourney Biologics has been joined by specialists in the field such as Tariq Ghayur (formerly Abbvie) and Rene Hoet (formerly Bayer), creating a panel of available scientists as service to support complex antibody projects. From target validation up to cell line development and pre-CMC reporting, FairJourney Biologics is a one stop shop leader in antibody services. As of 2022, the company has a headcount of above 200 staff members and a track record of more than 800 projects on a variety of areas.